​

Funding Round

Post-IPO Equity - Q32 Bio

Post-IPO Equity - Q32 Bio

Investment Firm

Overview

Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.

Announced Date

Mar 25, 2024

Closed on Date

Mar 25, 2024

Funding Type

Post Ipo Equity

Highlights

Location

United States, North America

Social

Investor Lead

N/A

Participant Investors

9

Investor Name
Participant InvestorAbingworth
Participant InvestorBristol-Myers Squibb
Participant InvestorAtlas Venture
Participant InvestorAcorn Bioventures
Participant InvestorOUP (Osage University Partners)

Round Details and Background

Q32 Bio raised $42000000 on 2024-03-25 in Post-IPO Equity

Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
May 27, 2020
Series A - Q32 Bio
6-46.0M
Oct 29, 2020
Series B - Q32 Bio
8-60.0M
Mar 25, 2024
Post-IPO Equity - Q32 Bio
10-42.0M

Recent Activity

There is no recent news or activity for this profile.